Welcome to our dedicated page for Baxter Intl news (Ticker: BAX), a resource for investors and traders seeking the latest updates and insights on Baxter Intl stock.
Baxter International Inc. (NYSE: BAX) is a global medtech company whose news flow reflects its focus on connected care technologies, medical devices and advanced injectable therapies. On this page, readers can follow company announcements that illustrate how Baxter’s products and partnerships intersect with hospital operations, nursing workflows and patient safety.
Recent Baxter news highlights the launch of the Dynamo Series smart stretcher, designed for emergency departments, perioperative environments and patient transport services. Baxter reports that the Dynamo Series is intended to reduce the need for patient transfers, support a range of procedures in-stretcher, and incorporate technologies such as SafeView+ visual cues, bed exit alarms and optional connectivity to EMRs and nurse call systems to help prevent patient falls and support care teams.
Other updates include a multi-year strategic partnership with MUSC Health focused on integrating connected care technologies at the bedside. Baxter and MUSC Health describe objectives such as standardizing and simplifying bedside technologies, reducing documentation time, streamlining communication, improving nurse satisfaction and retention, and using real-time insights and advanced monitoring to enhance quality and safety outcomes.
Baxter also issues news on its infusion therapy portfolio, such as real-world data presented with The University of Texas Medical Branch on the Spectrum IQ large volume infusion pumps. These analyses examine how smart pump integration with electronic medical records may affect patient safety alerts, infusion programming time and clinician workload.
In addition, investors can find announcements on capital allocation decisions, including tender offers for senior notes, new note issuances and dividend declarations, as well as philanthropic news from the Baxter Foundation, such as grants to support STEM education through the Baxter Center for Science Education. Bookmark this page to access Baxter’s latest product, partnership, financial and community impact news in one place.
Baxter International (NYSE:BAX) has received FDA 510(k) clearance for its ST Set, enhancing continuous renal replacement therapy (CRRT) options. Previously authorized under Emergency Use Authorization due to COVID-19, the ST Set includes three sizes and utilizes Baxter's proprietary AN69 membrane for effective blood purification. This approval is expected to meet the increased demand for CRRT amid rising acute kidney injury cases, thereby expanding patient access to critical care solutions. The ST Set is already in use across multiple regions, including Europe and Asia Pacific.
Baxter International Inc. (NYSE:BAX) will host a conference call on April 28, 2022, at 7:30 a.m. Central Time to discuss its first-quarter financial results. Participants can pre-register for the call via the provided link. The call will also be webcasted on Baxter's website. Baxter is a leading global medtech company providing critical care, kidney care, and other medical products used widely across healthcare settings.
Baxter International Inc. (NYSE:BAX), a leader in medtech, will present at the Barclays Global Healthcare Conference on Thursday, March 17, 2022, at 8:00 a.m. ET. Jay Saccaro, Baxter's CFO, will be presenting. Investors can access the live webcast on Baxter's website, with a replay available until September 13, 2022. The company has a portfolio of products serving patients worldwide, highlighting its commitment to innovative healthcare solutions for nearly 90 years.
Baxter International (NYSE:BAX) has released new data indicating that its Sharesource remote patient management platform may enhance clinical effectiveness for home dialysis patients. A study presented at the World Congress of Nephrology showed that patients using Sharesource experienced an average increase of 3.4 months in time on therapy compared to those without the platform. This research involved nearly 1,500 patients in Colombia over a two-year period, supporting the growing evidence that digital health solutions are beneficial in kidney care.
Baxter International (NYSE:BAX) has been authorized as a CVE Numbering Authority by the Common Vulnerabilities and Exposures (CVE®) program. This designation allows Baxter to assign CVE identifiers to cybersecurity vulnerabilities in its products, enhancing the company's efforts to tackle rising cybersecurity threats in healthcare. Cyberattacks on healthcare organizations have surged 45% since Nov. 2020. The CVE program, backed by the U.S. Department of Homeland Security, aims to expedite the identification and resolution of cybersecurity vulnerabilities, thereby supporting patient care.
Baxter International Inc. (NYSE:BAX) will present at the Raymond James 43rd Annual Institutional Investors Conference on March 7, 2022, with CFO Jay Saccaro scheduled to speak at 8:40 a.m. Eastern Time. A live webcast can be accessed via www.baxter.com and will be available for replay until March 6, 2023. Baxter has been a leader in medtech for 90 years, providing essential healthcare products across various sectors.
Baxter International reported Q4 sales of $3.5 billion, a 10% increase, while full-year revenue reached $12.8 billion, up 10%. GAAP EPS for Q4 was $0.47 and adjusted EPS was $1.04, with full-year GAAP EPS at $2.53 and adjusted EPS at $3.61. The company's recent acquisition of Hillrom, effective Dec. 13, 2021, is projected to enhance top-line growth and innovation. Despite challenges from COVID-19, Baxter achieved significant growth across its product segments. The 2022 outlook projects reported sales growth of 24%-25% and adjusted earnings of $4.25-$4.35 per diluted share.
Baxter International Inc. (NYSE:BAX) has declared a quarterly cash dividend of $0.28 per share, payable on April 1, 2022, to shareholders recorded by February 25, 2022. This brings the annual dividend rate to $1.12 per share. As a leading medtech company, Baxter continues to support patients and healthcare providers globally with innovative products across various medical sectors.
Baxter International Inc. (NYSE:BAX) will present at Citi's 2022 Virtual Healthcare Conference on February 23, 2022, at 1:15 p.m. Eastern Time. Chief Financial Officer Jay Saccaro is scheduled to deliver the presentation. A live webcast will be accessible at www.baxter.com and can be replayed until February 22, 2023.
Baxter provides crucial healthcare solutions, operating in over 100 countries for nearly 90 years. They focus on advancing innovative healthcare products and therapies.
Baxter International and the Thurgood Marshall College Fund have launched the Baxter HBCU STEM Scholars Program, a $3.5 million initiative aimed at supporting students from Historically Black Colleges and Universities (HBCUs) in STEM fields. The program will offer scholarships and mentorship to approximately 40 students over three years, addressing the low graduation rates among Black students (44% compared to 63% overall). The initiative also enhances teacher retention through mentorship for Black and Brown educators.